AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06792370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to Use Therapeutic Food - Standard dose
Description: Each child with SAM will be treated with a standard dose (according to the national protocol for the integrated management of acute malnutrition in Burkina Faso) for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery.
Study NCT06792370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food - Reduced dose 2
Description: Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until the child is no longer severely malnourished and does not have nutritional oedema then 100-130 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
Study NCT06790459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UlfTens (Ultra-low-frequencies Transcutaneous electrical nervous stimulation)
Description: ULFTENS device will be administered in the experimental group for 15 minutes
Study NCT06791759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The course on technology use in nursing
Description: Students attended in the course technology use in nursing. The course consisted of 2 hours per week over 14 weeks. The course aims to provide students with an understanding of fundamental technological developments in nursing, highlighting the importance and impact of technology in nursing education and practice.Theoretical lessons were delivered by two nurse educators over 8 weeks through PowerPoint presentations and interactive discussions. For the remaining five weeks, students were given some assignments to increase their interaction with digital technological tools. Three assignments were planned for each of the students. In this context, microsoft teams, canva, microsoft powerpoint, kahoot, mentimeter, quizlet, ed-puzzle, capcut, mobile health applications, google classroom, discord and artificial intelligence applications were used for assignments.
Study NCT06790888 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ripertamab/Eltrombopag
Description: Ripertamab, a novel anti-CD20 monoclonal antibody, in combination with Eltrombopag . Ripertamab is administered intravenously at a dose of 375 mg/m² BSA on Day 1 . If the participant remains in remission at the 3-month mark, an additional intravenous dose of 375 mg/m² Ripertamab is administered. Eltrombopag are given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
Study NCT06790888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
Study NCT06791928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer distribution of self testking kits
Description: Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
Study NCT06791928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer distribution of self testking kits
Description: Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
Study NCT06791083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 150mg/m2 , IH， d1；Q3W
Study NCT06791083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5 mg ，po，QD，d1-d14；Q3W
Study NCT06792305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Starting by anterior ring fixation in vertical shear pelvic ring injuries
Description: The procedure will involve addressing the pelvic ring anteriorly with open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate. The goal isto achieve anatomical reduction and stable fixation to restore the integrity of the pelvic ring. Fixation of the posterior ring will be achieved using a single sacroiliac screw in S1. The goal of posterior fixation is to achieve stability and alignment of the posterior pelvic structures.
Study NCT06792305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Starting by posterior ring fixation in vertical shear pelvic ring injuries
Description: the procedure will involve fixation of the posterior ring which will be achieved by using a single sacroiliac screw in S1. Then open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate.
Study NCT06791005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Injection of Carbon Nanoparticles
Description: 1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
Study NCT06791005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Injection of Carbon Nanoparticles
Description: Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
Study NCT06790277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border Sacrum dressings
Description: Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
Study NCT06790277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane foams (Pink Pad)
Description: Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
Study NCT06791577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Application of the intervention (CO2 Lift) in the area according to the protocol schedule
Study NCT06791577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of the placebo (Vaseline) in the area according to the protocol schedule
Study NCT06790433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibraject
Description: The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis. The Vibraject was activated after aspiration to deposit the solution slowly at approximately 50 seconds. Following cartridge deposition, the operator adjusted the participant to an upright seated position
Study NCT06790433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentapen
Description: The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis (needle placement). The Dentapen was activated after aspiration to deposit the solution at a medium rate (1 mL/60 s) using the ramp-up mode. Following cartridge deposition, the operator adjusted the participant to an upright seated position
Study NCT06787079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio tape is a non-invasive therapeutic approach that does not involve any medication. It is often used to support tissue and reduce pain.
Study NCT06787079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
Study NCT06787079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
Study NCT06787079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
Study NCT06787079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taping will be applied in the same way as kinesio taping, but with plaster tape.
Study NCT06790602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab Plus Gemcitabine
Description: Cemiplimab Plus Gemcitabine
Study NCT06791590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent oro-esophageal
Description: A disposable gastric tube was used to perform enteral nutrition support therapy, and contraindications were evaluated again. Inform the patient and family members of the precautions for intermittent feeding through oral tube, and play the video of the operation process to make them actively cooperate with the operation.
Study NCT06791590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naso-intestinal tube nutrition support
Description: For patients at risk of repeated aspiration and regurgitation, and for patients with gastric nutritional intolerance that cannot be improved by gastrointestinal motivity drugs, indwelling intestinal tube and retropyloric feeding are given.
Study NCT06792123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-op VR application group
Description: VR application group during preoperative process
Study NCT06792123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-op VR application group
Description: VR application group during intraoperative process
Study NCT06790823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The probiotic supplement (Moodamin capsuls)
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
Study NCT06790823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
Study NCT06792214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Paxlovid PO BID for 5 days + standard of care
Study NCT06792214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Veklury IV daily for 5 days + standard of care
Study NCT05160012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Comparison Message
Description: In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer
Study NCT06495320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational drug use education
Description: Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
Study NCT05628870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1358
Description: HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
Study NCT05628402 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
Study NCT04882358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM
Description: Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
Study NCT04882358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: treatment with a standard dose of SGLT-2 inhibitor
Study NCT05349214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: ianalumab s.c.
Study NCT05314543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
Study NCT05131529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste-focused labels
Description: We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger).
Study NCT05349214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c.
Study NCT05131529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon impact labels
Description: We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
Study NCT05131529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing default menu options
Description: We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
Study NCT04816045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotheraoy
Description: Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
Study NCT04816045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroporation with saline (placebo)
Description: Electroporation in the control group is performed endoscopically with saline
Study NCT06490614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine in superficial cervical plexus block
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
Study NCT06494345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genolair, solution for subcutaneous administration, 150 mg
Description: Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
Study NCT06494345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Genolair, lyophilisate for the preparation of solution for subcutaneous administration
Description: Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
Study NCT06494345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair®, solution for subcutaneous administration, 150 mg
Description: Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
Study NCT05778864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.
Study NCT04714944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation period 12 weeks
Study NCT04714944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole fiber product
Description: Supplementation period 12 weeks
Study NCT05074667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care